Methotrexate mechanism in treatment of rheumatoid arthritis

Weinblatt, 1985, Efficacy of low-dose methotrexate in rheumatoid arthritis, N Engl J Med, 312, 818, 10.1056/NEJM198503283121303

Visser, 2009, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, 68, 1094, 10.1136/ard.2008.092668

Visentin, 2012, The antifolates, Hematol Oncol Clin North Am, 26, 629, 10.1016/j.hoc.2012.02.002

Whittle, 2004, Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review, Rheumatology (Oxford), 43, 267, 10.1093/rheumatology/keh088

Pichlmeier, 2014, Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate, Clin Exp Rheumatol, 32, 563

Desmoulin, 2012, The human proton-coupled folate transporter: Biology and therapeutic applications to cancer, Cancer Biol Ther, 13, 1355, 10.4161/cbt.22020

Seideman, 1993, The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis, Br J Clin Pharmacol, 35, 409, 10.1111/j.1365-2125.1993.tb04158.x

Nuernberg, 1990, Biliary elimination of low-dose methotrexate in humans, Arthritis Rheum, 33, 898, 10.1002/art.1780330620

Godfrey, 1998, The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis, Br J Clin Pharmacol, 46, 369, 10.1046/j.1365-2125.1998.t01-1-00790.x

Angelis-Stoforidis, 1999, Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis, Clin Exp Rheumatol, 17, 313

Brown, 2016, Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers, Nat Rev Rheumatol, 731, 10.1038/nrrheum.2016.175

Budzik, 2000, Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line, Life Sci, 66, 2297, 10.1016/S0024-3205(00)00559-2

Fairbanks, 1999, Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?, Biochem J, 342, 143, 10.1042/bj3420143

Cronstein, 2017, Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases, Nat Rev Rheumatol, 13, 41, 10.1038/nrrheum.2016.178

Baggott, 1986, Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5’-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide, Biochem J, 236, 193, 10.1042/bj2360193

Hasko, 2008, Adenosine receptors: therapeutic aspects for inflammatory and immune diseases, Nat Rev Drug Discov, 7, 759, 10.1038/nrd2638

Varani, 2011, A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release, Arthritis Res Ther, 13, R197, 10.1186/ar3527

Varani, 2009, Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate, Arthritis Rheum, 60, 2880, 10.1002/art.24794

Nguyen, 2003, The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis, J Immunol, 170, 3337, 10.4049/jimmunol.170.6.3337

Cronstein, 1991, Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells, Proc Natl Acad Sci U S A, 88, 2441, 10.1073/pnas.88.6.2441

Cronstein, 1993, The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation, J Clin Invest, 92, 2675, 10.1172/JCI116884

Montesinos, 2006, Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis, Arthritis Res Ther, 8, R53, 10.1186/ar1914

Montesinos, 2007, The anti-inflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5’-nucleotidase: findings in a study of ecto-5’-nucleotidase gene-deficient mice, Arthritis Rheum, 56, 1440, 10.1002/art.22643

Morabito, 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5’-nucleotidase-mediated conversion of adenine nucleotides, J Clin Invest, 101, 295, 10.1172/JCI1554

Huang, 1997, Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T cell activation and expansion, Blood, 90, 1600, 10.1182/blood.V90.4.1600

Koshiba, 1997, Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells, J Biol Chem, 272, 25881, 10.1074/jbc.272.41.25881

Peres, 2016, Dispersal limitation induces long-term biomass collapse in overhunted Amazonian forests, Proc Natl Acad Sci U S A, 113, 892, 10.1073/pnas.1516525113

Feoktistov, 2009, Adenosine receptors in wound healing, fibrosis and angiogenesis, Handb Exp Pharmaco, 193, 383, 10.1007/978-3-540-89615-9_13

Teramachi, 2011, Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis, Lab Invest, 91, 719, 10.1038/labinvest.2011.9

Phillips, 2003, The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species, Br J Pharmacol, 138, 501, 10.1038/sj.bjp.0705054

Spurlock, 2011, Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK, Arthritis Rheum, 63, 2606, 10.1002/art.30457

Dolhain, 1998, Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis, Br J Rheumatol, 37, 502, 10.1093/rheumatology/37.5.502

Johnston, 2005, The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules, Clin Immunol, 114, 154, 10.1016/j.clim.2004.09.001

Klimiuk, 2007, Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis, Scand J Rheumatol, 36, 345, 10.1080/03009740701406460

Sands, 2004, Specific inhibition of nuclear factor-kappaB-dependent inflammatory responses by cell type-specific mechanisms upon A2A adenosine receptor gene transfer, Mol Pharmacol, 66, 1147, 10.1124/mol.104.001107

Gerards, 2003, Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis, Rheumatology (Oxford), 42, 1189, 10.1093/rheumatology/keg323

Rudwaleit, 2000, Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4, Ann Rheum Dis, 59, 311, 10.1136/ard.59.4.311

Miranda-Carus, 2004, L-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate, J Immunol, 173, 1463, 10.4049/jimmunol.173.2.1463

Chan, 2010, Methotrexate – how does it really work?, Nat Rev Rheumatol, 6, 175, 10.1038/nrrheum.2010.5

Nesher, 1991, In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine, Ann Rheum Dis, 50, 637, 10.1136/ard.50.9.637

Kremer, 1986, Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates, Arthritis Rheum, 29, 832, 10.1002/art.1780290703

Puig, 1984, Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate, J Clin Invest, 74, 936, 10.1172/JCI111512

Chan, 2006, Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis, Br J Pharmacol, 148, 1144, 10.1038/sj.bjp.0706812

Montesinos, 2002, Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors, Am J Pathol, 160, 2009, 10.1016/S0002-9440(10)61151-0

Merrill, 1997, Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis, Arthritis Rheum, 40, 1308

Shea, 2013, Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis, Cochrane Database Syst Rev, CD000951

Morgan, 1994, Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial, Ann Intern Med, 121, 833, 10.7326/0003-4819-121-11-199412010-00002

Kurzawski, 2016, ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients, Pharmacogenomics, 17, 1971, 10.2217/pgs-2016-0125

Lee, 2016, Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis, Rheumatol Int, 36, 1591, 10.1007/s00296-016-3523-2

Li, 2016, The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis, Int Immunopharmacol, 38, 8, 10.1016/j.intimp.2016.05.012

Lima, 2016, Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome, Pharmacogenomics, 17, 1649, 10.2217/pgs-2016-0067

Hider, 2008, Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX, Rheumatology (Oxford), 47, 1156, 10.1093/rheumatology/ken182

Bartelds, 2011, Development of anti-drug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up, JAMA, 305, 1460, 10.1001/jama.2011.406

Pascual-Salcedo, 2011, Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology (Oxford), 50, 1445, 10.1093/rheumatology/ker124

Bartelds, 2007, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis, 66, 921, 10.1136/ard.2006.065615

Bartelds, 2010, Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study, Ann Rheum Dis, 69, 817, 10.1136/ard.2009.112847

Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

Bendtzen, 2006, Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab, Arthritis Rheum, 54, 3782, 10.1002/art.22214

Krieckaert, 2010, The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review, Arthritis Res Ther, 12, 217, 10.1186/ar3147

Jani, 2014, The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases, Rheumatology (Oxford), 53, 213, 10.1093/rheumatology/ket260